PTC Therapeutics gets the Forbes treatment

Forbes is profiling the development work underway at the "unknown" PTC Therapeutics, one of this year's Fierce 15. The feature focuses on the progress of PTC124 in mid-stage trials for Duchenne muscular dystrophy, noting that it has the potential to address a myriad of other genetic flaws as well.

- read the article on PTC Therapeutics from Forbes

Related Articlex:
Genetic therapy could cure 1,800 diseases. Report
Schering-Plough, PTC to collaborate. Report
PTC inks deal with CV. Report